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Abstract
Background: Natalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4
(VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to
study impacts of Natalizumab therapy on Foxp3+ T regulatory cells (Tregs) in multiple sclerosis (MS) patients.
Methodology: A combined approach of in vitro and ex vivo experiments using T cells isolated from the peripheral blood of
healthy donors and Natalizumab treated MS patients was chosen. We determined binding of Natalizumab and its effects on
the frequency, transmigratory behaviour and suppressive function of Tregs.
Principal Findings: Binding of Natalizumab and expression of CD49d (alpha-4 chain of VLA-4) differed between non-
regulatory and regulatory cells. Albeit Foxp3+ Tregs had lower levels of CD49d, Natalizumab blocked the transmigration of
Foxp3+ Tregs similar to non-regulatory T cells. The frequency of peripheral blood Tregs was unaffected by Natalizumab
treatment. Natalizumab does not alter the suppressive capacity of CD4+CD25
highCD127
lowFoxp3+ Tregs under in vitro
conditions. Furthermore, the impaired function of Tregs in MS patients is not restored by Natalizumab treatment.
Conclusions: We provide a first detailed analysis of Natalizumab effects on the regulatory T cell population. Our prospective
study shows that Foxp3+ Tregs express lower levels of VLA-4 and bind less Natalizumab. We further the understanding of
the mechanisms of action of Natalizumab by demonstrating that unlike other immunomodulatory drugs the beneficial
therapeutic effects of the monoclonal antibody are largely independent of alterations in Treg frequency or function.
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Introduction
Natalizumab (TysabriH), a monoclonal humanized antibody
(mAb) targeting the alpha-4 chain of a4b1 (very late activation
antigen 4; VLA-4) and a4b7 integrins on the surface of leukocytes,
exerts impressive therapeutic effects in patients with relapsing-
remitting multiple sclerosis [1–3]. However, clinical efficacy is
opposed to some uncertainty about the risk-benefit profile
associated to treatment [4–6], especially given the fact that 3
cases of progressive multifocal leukoencephalopathy (PML) have
been reported in association to Natalizumab treatment in the
setting of clinical trials [7,8].
It is believed that this mAB inhibits the interaction between
VLA-4 on the leukocyte surface and its respective ligand on
endothelial cells (VCAM-1), thereby preventing the extravasation
of leukocytes into the central nervous system (CNS) [4,9]. Besides
its effects on leukocyte transmigration, Natalizumab may elicit
direct effects on T cell function. The therapeutic target of
Natalizumab belongs to the large group of integrins, which are
considered bi-directional signalling molecules [10]. VLA-4 forms
an essential part of the immunological synapse and ligation of
VLA-4 was demonstrated to provide costimulatory signals to T
cells [11–13]. However, despite strong clinical evidence for the use
of Natalizumab in patients, knowledge on biological effects on
different immune cell populations in MS patients in vivo is still
marginal [13–15].
Recent work supports the hypothesis that Natalizumab does not
uniformly block lymphocyte extravasation but might act via
selective modulation of its cellular targets. VLA-4 surface levels
were demonstrated to differ considerably between specific immune
cell subsets and analysis of cerebrospinal fluid in Natalizumab
treated patients supports the idea that Natalizumab preferentially
blocks extravasation of CD4+ over CD8+ T cells [13,14]. These
findings are of particular interest since a differential effect of
Natalizumab on specific immune cell subsets might have major
implications for the immunesurveillance of the CNS and could
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in Natalizumab treated patients.
Thymus derived (natural) Foxp3+ Tregs are an emerging
immune cell population crucial for the maintenance of immune-
tolerance and pivotal for the control of autoimmune and infectious
disorders [16,17]. If and how Natalizumab affects this regulatory
T cell population is currently unknown. We here prospectively
studied how Natalizumab binds to Tregs and delineated the effect
on frequency, migratory behaviour and suppressive function of
Foxp3+ T regulatory cells and their non-regulatory counterparts.
Results
Natalizumab binding to different T cell subsets
We first assessed how Natalizumab binds to Foxp3+ Tregs
versus Foxp3 negative CD4+ T cells. After evaluating the
saturation of Natalizumab binding sites using FITC-conjugated
Natalizumab, a saturating dose of Natalizumab (20 mg/ml) was
used to assess a differential binding to T cell subsets. The
concentration of 20 mg/ml lies within the range of serum trough
levels of treated patients [9]. A comparison of the specific
fluorescent indices (SFI) of CD4+ and CD8+ T cells in untreated
MS patients revealed significantly higher binding of Natalizumab
to CD8+ T cells (Figure 1a). In contrast, binding of Natalizumab
to the CD4+Foxp3+ subset of regulatory T cells was significantly
lower compared to their CD4+Foxp3 negative counterparts, both
in healthy donors and MS patients (Figure 1b). The disease course
(acute relapse versus stable; n=5 each) had no effect on
Natalizumab binding to T cell subsets derived from the peripheral
blood of MS patients (data not shown).
As Natalizumab bindingto the alpha-4 chainof VLA-4 and a4b7
is independent of a conformational active state, the differential
binding of Natalizumab to Tregs and their Foxp3 negative
counterparts should be closely mimicked by the expression levels
of CD49d on the cell surface. Thus, we analyzed the surface
expression of alpha-4 integrin (CD49d) by the use of a distinct
antibody recognizing the B epitope of CD49d (9F10). In line with
our findings on Natalizumab binding, CD49d levels on Foxp3+
CD4+ T cells were much lower compared to the non-regulatory
CD4+ population (Figure 1c). There were no differences in CD49d
expression levels between Foxp3+ Tregs derived from MS patients
as compared to healthy donors (Figure 1c).
Previously published data suggests that the differential impact of
in vivo Natalizumab treatment on the function of immune cells is
closely reflected by a relative decrease of CD49d immunoreactivity
on the surface of leukocytes after initiation of therapy [13]. Ex vivo
analysis of CD49d surface expression revealed a significant
decrease on all immune cell populations under investigation 30
days after the first infusion of Natalizumab. The relative impact of
Natalizumab infusion (percent of MFI) was significantly higher for
Figure 1. Differential binding of Natalizumab to T cell subsets. (A) Binding of FITC-conjugated Natalizumab (20 mg/ml) to CD4+ and CD8+ T
cells derived from patients with a relapsing-remitting disease course (RRMS; n=9) and (B) to regulatory, Foxp3+ and non-regulatory, Foxp32 CD4+ T
cells from healthy donors (HD; n=9) and RRMS patients (n=10) as analyzed by flow cytometry. (C) Differences in Natalizumab binding closely reflect
surface expression patterns of the a4 chain (CD49d) of VLA-4 as analyzed by flow cytometry. (D) CD49d surface levels were analyzed by flow
cytometry before (light grey) and 1 month after initiation of therapy with Natalizumab (dark grey). Postinfusion levels were normalized to the
expression of CD49d before treatment. The relative loss of functional VLA-4 is lower in CD4+Foxp3+ T regulatory cells than in conventional CD4+ T
cells (n=15). SFI=specific fluorescent index, * p,0,05; **p,0,005, student’s t-test.
doi:10.1371/journal.pone.0003319.g001
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treatment resulted in a 51% reduction of CD49d immunoreac-
tivity on CD4+ T cells whereas Foxp3+ Tregs were less affected
resulting in a 32% reduction of CD49d on the Treg surface
(n=15, Figure 1d). Conversely, there was no difference between
the relative loss of surface CD49d on CD4+ and CD8+, which is in
line with previously published observations by Stu ¨ve and
colleagues [14] (n=11, data not shown). Of note, the impact of
Natalizumab as measured by decrease of CD49d SFI on T cells
directly correlates with the presence of neutralizing antibodies
against Natalizumab: one patient in our cohort showed an initial
decrease of CD49d immunoreactivity at M1, followed by a return
to baseline at M6 (Supplementary Figure S1). He was shown to
have persisting neutralizing antibodies in parallel.
Effects of Natalizumab on the migration of T effector cells
and Tregs
It is currently unknown how the migratory behaviour differs
between Foxp3+ Tregs and Foxp32 CD4+ T cells in MS patients
and how blockade of VLA-4 influences migration of Tregs.
According to Niino et al., the relative loss of CD49d immunore-
activity under in vivo therapy directly correlates with the migratory
behaviour of immune cell subsets as demonstrated for monocytes,
B and T lymphocytes [13]. Since expression of CD49d was
significantly lower in Foxp3+ Tregs than in Foxp32 T cells and
the relative decrease of CD49d immunoreactivity in the presence
of Natalizumab was significantly lower on Foxp3+ Tregs
compared to conventional CD4+ (Figure 1), we were curious if
this finding might be associated with an aberrant migratory
behaviour. To assess transmigration of CD4+ T cells we used
fibronectin coated Boyden chambers, a well characterized
experimental set-up to assess transmigration mediated by interac-
tion of VLA-4 on the T cell surface with its alternative binding
partner, the CS-1 fragment of fibronectin [13,20]. In line with
previous findings by Niino et al. Natalizumab blocked T cell
transmigration in this experimental setting (data not shown). To
find out whether Natalizumab might favour the migration of
Tregs, we assessed the percentage of Foxp3+ T cells at baseline
and within the migrated fraction. A selective blockade of non-
regulatory CD4+ compared to Tregs should have resulted in an
enrichment of Foxp3+ T cells within the migrated fraction.
However, the percentage of Foxp3+ T cells within the migrated
fraction remained the same irrespective of Natalizumab treatment
(n=15, Figure 2).
Foxp3+CD4+ T cell frequency in patients undergoing
Natalizumab therapy
VLA-4 blockade is associated with an increase of the absolute
lymphocyte numbers in the peripheral blood of MS patients [2,3],
however, flow cytometrical analysis of Foxp3+ T regulatory cells in
patients treated with Natalizumab demonstrated that Treg
frequency was not significantly affected by therapy 30 days after
Natalizumab application (n=15, Figure 3a). In accordance with
our protein data, mRNA analysis of FOXP3 expression levels on
PBMC before and 3 months after the first infusion yielded
comparable results (n=5, Figure 3b).
Natalizumab does not restore the impaired suppressive
function of Tregs in MS
Besides blocking the interaction between VLA-4 and its ligand
on endothelial cells, direct effects of Natalizumab on T cell
function have been proposed to contribute to the beneficial effects
of Natalizumab in MS. VLA-4 blockade has been reported to
modulate the activation state of CD4+ T cells [13,25]. Foxp3+
Tregs have been described to be dysfunctional in the MS patient
Figure 2. Natalizumab blocks both Tregs and non-regulatory T
cells in in vitro transmigration assays. CD4+ T cells were analyzed
for their migratory capacity in a fibronectin coated Boyden chamber
assay system. The relative proportion of Foxp3+ cells before migration
(periphery) and within the migrated fraction (migrated) was assessed by
multicolour flow cytometry. The bar diagram demonstrates the
frequency of Foxp3+ T cells in the two fractions before and after
initiation of Natalizumab therapy (n=15). No differences were observed
under any condition.
doi:10.1371/journal.pone.0003319.g002
Figure 3. Frequency and mRNA of CD4+Foxp3+ T regulatory cells are not altered by Natalizumab therapy. (A) The frequency of
CD4+Foxp3+ Tregs was determined by flow cytometry before and 30 days after the first infusion. (B) Foxp3 mRNA expression levels as analyzed by
real-time PCR before and 3 months after initiation of therapy (n=5).
doi:10.1371/journal.pone.0003319.g003
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zumab may influence the suppressive function of Foxp3+ T
regulatory cells. To allow a direct comparison of the suppressive
capacity of MS patient derived Tregs before and after initiation of
Natalizumab therapy we had to rely on frozen PBMC samples to
conduct functional suppression assays. Flow cytometry of human
lymphocytes thawed after cryopreservation in liquid nitrogen
reveals a strong reduction in CD25 immunoreactivity as compared
to freshly isolated lymphocytes ([18] and observations in our own
laboratory). Sequential flow cytometrical analysis demonstrated
that a 3 day culture period was necessary for the CD25 surface
expression to fully recover, thus allowing the distinction of
regulatory and non-regulatory T cells. Several methods of cell
purification were evaluated to guarantee a high purity of Tregs.
However, neither magnetic cell purification using a commercially
available Treg purification kit (Miltenyi Biotec, Bergisch-Glad-
bach, Germany), nor fluorescence activated cell sorting for the
CD4+CD25
high population yielded the desired purity as demon-
strated by intracellular staining for Foxp3 on purified T cell subsets
(Supplementary Figure S2a). However, the additional staining for
the recently described marker CD127 (IL-7 receptor) distinguish-
ing Tregs from non-regulatory cells [28,29] and gating on the
CD4+CD25
highCD127
low population helped to consistently isolate
highly pure (.95%) Foxp3+ Tregs by fluorescence activated cell
sorting (Supplementary Figure S2b). Using this protocol, purity of
the CD4+CD25
highCD127
low T regulatory cells as assessed by
Foxp3 expression was comparable between cryopreserved PBMC
and freshly isolated cells. Parallel suppression assays using either
freshly or previously cryopreserved T regulatory cells derived from
the same healthy donor demonstrated that the suppressive
function was not affected.
In contrast to Tregs derived from the peripheral blood of
healthy donors, MS patient derived Tregs showed very poor
suppression of autologous T cell proliferation as a baseline (31%
versus 4% mean suppression, at a 1:10 Treg to responder ratio;
n=5 for healthy donors and MS patients respectively). Addition of
Natalizumab to the aCD3/aCD28 microbead-based suppression
assays showed no significant influence on the suppressor function
of Foxp3+ regulatory T cells (experiments performed with Tregs
derived from healthy donors; one out of 5 representative
experiment is shown, Figure 4a). Various concentrations of
Natalizumab (0,5 mg/ml up to 40 mg/ml) and titration of
suppressor:effector ratios in modification of the assay conditions
yielded comparable results (data not shown). We tested the effect
of Natalizumab treatment on the suppressive function of Tregs in
ex vivo aCD3/aCD28 microbead-based suppression experiments.
In line with our in vitro data, treatment with Natalizumab did not
alter the dysfunctional suppressive capacity of T regulatory cells in
patients with RRMS. Over 6 months of treatment, highly pure
CD4+CD25
highCD127
low regulatory cells remained poor suppres-
sors (n=5, Figure 4b). In addition to bead-based suppression
assays we used allogeneic immature and mature DC to challenge
T effector cells. Since VLA-4 is part of the immunological synapse
and has been suggested to be involved in costimulation [11–13] we
first investigated whether Natalizumab influences the outcome of
DC-T cell encounters by modulating T cell proliferation.
However, Natalizumab (20 mg/ml) did not impact the percentage
of proliferating T cells in response to immature DC (23,96+/
210,57 vs. 24,58+/214,02) or mature DC (39,324+/214,77 vs.
39,178+/216,67) as determined by CFSE dilution assays (n=5,
Figure 4c). APC-based suppression assays revealed that
CD4
+CD127
lowCD25
high Treg cells derived from healthy donors
strongly suppressed the proliferation of T effector cells challenged
by allogeneic DC, as exemplarily depicted for immature DC
(Figure 4c). VLA-4 blockade by addition of Natalizumab (20 mg/
ml) did not affect the Treg mediated suppression in the presence of
immature DC (Figure 4d). Similar results were obtained when LPS
matured DC were used instead of immature DC (data not shown).
Further analysis confirmed that Tregs derived from MS patients
remained dysfunctional in this APC-based suppression assay
(Figure 4e, n=4). Ex vivo experiments using T effectors and T
regulatory cells derived from Natalizumab treated patients before
and after initiation of therapy (month 1 and 6) did not reveal a
significant effect on the suppressive capacity of
CD4
+CD127
lowCD25
high Treg in the presence of allogeneic
immature DC, albeit a trend towards a regain of function could
be noted (Figure 4e, n=4).
Discussion
Our study investigated the influence of Natalizumab therapy on
the Foxp3+ T regulatory cell population. Regulatory T cells
recently emerged as key players in orchestrating adaptive immune
responses and balancing immune tolerance versus autoimmunity
[16,30]. A role in the immune surveillance of parenchymal organs
including the CNS is assumed as recent studies have suggested that
Foxp3+ Tregs are capable of migrating into the CNS under
inflammatory conditions and may actively modulate the function
of effector cells within the target organ itself. During experimental
autoimmune encephalomyelitis (EAE), peripherally expanded
Tregs are found to accumulate within the CNS [31], and Foxp3+
Tregs were demonstrated to be enriched in the CSF of MS
patients contributing to the hypothesis that natural Tregs may be
actively ‘‘recruited’’ to the site of inflammation in MS [23,32].
VLA-4 has been identified as a crucial molecule in T cell
trafficking across the blood-brain barrier and VLA-4 blockade by
Natalizumab efficiently inhibits migration of T effector cells into
the CNS [15]. It is well perceivable that differential effects of
Natalizumab on the migratory capacity or functional properties of
non-regulatory and Foxp3+ T regulatory cells would have
implications for CNS immunosurveillance.
Natalizumab was found to preferentially bind to T effector cells,
due to a lower expression of the target molecule (alpha-4 integrin)
on Tregs. This could either indicate a stronger impact of a given
dose of the mAB on Tregs or they could be less prone to
Natalizumab effects since other, yet unidentified molecules, might
be dominant in the control of Treg trafficking. It has been
suggested that instead of absolute levels of alpha-4 integrin, it is
rather the relative loss of functional VLA-4 under therapy which
dictates differential effects of Natalizumab on immune cell
subsets
13. In line with the literature Natalizumab therapy resulted
in a marked loss of alpha-4 integrin (CD49d) immunoreactivity on
all T cell subsets [13,14]. Interestingly, the relative decrease of
functional alpha-4 integrin was less pronounced in Tregs in
comparison to Foxp3 negative T cells suggesting that Natalizumab
may preferentially block the migration of T effector cells and thus
favour the extravasation of Tregs. To test this hypothesis we chose
a simplified but well characterized model system to assess
migration of T cells mediated by interaction of VLA-4 with its
alternate binding partner, the CS-1 fragment of fibronectin. This
experimental model has previously been used for analyzing alpha-
4 integrin mediated transmigration of lymphocytes [20,21] and
was found to closely and highly reliably reflect the effects of VLA-4
blockade on T cell trafficking [13]. Albeit the relative loss of
functional VLA-4 was significantly lower on Tregs, Natalizumab
treatment did not ‘‘favour’’ the transmigration of Foxp3+ Tregs.
Still, due to the limitations of the chosen in vitro model system our
data need to be interpreted carefully. Certainly, the best way to
Natalizumab Effects on Tregs
PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3319Figure 4. Natalizumab does not alter the suppressive capacity of CD4+CD25
highCD127
low Tregs and does not restore impaired Treg
function in MS. (A) CFSE-based suppression assays using fluorescence activated cell sorted T cells derived from the peripheral blood of healthy
donors were conducted in the presence or absence of Natalizumab (20 mg/ml). The proliferation of responder T cells (CD4+CD252) was suppressed
in the presence of Tregs as analyzed by flow cytometry, however, the suppressive capacity of Tregs remained unaffected by the mAb. One out of 5
representative experiments is shown, the percentage of proliferating cells is indicated in the diagram. (B) Suppressive capacity of serially analyzed T
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patients under treatment, thereby comparing the frequency of
Tregs within the CSF before and after initiation of therapy (e.g. at
6 or 12 months). However, we refrained from attempting this for
both technical as well as medical-ethical reasons. Under VLA-4
blockade CSF cell counts are markedly diminished in treated
patients [15]. Since Foxp3 cells represent a minority within the
CD4 T cell populations, conclusions from flow cytometrical
analysis would have been based on extremely low number of Tregs
cells. Furthermore, no patient in our cohort underwent lumbar
puncture for medical reasons under the prospective study period.
It has been suggested that the loss (and regain) in functional
VLA-4 under therapy may be a useful biomarker to monitor
individual responses to Natalizumab therapy which hold true in
our study [13]. The loss of alpha-4 integrin expression was well
sustained at the end of the monthly dosing interval, even after
receiving only 1 infusion of Natalizumab (300 mg i.v.). Although
being based on a single observation, the finding that persistent
neutralizing antibodies seem to abrogate the functional loss of
VLA-4 under therapy strengthens the potential role of this
biomarker in monitoring Natalizumab therapy and warrants
further investigations.
We challenged the influence of Natalizumab on T suppressor
frequency and function. Tregs play a key role in the mechanisms
of autoimmunity, a loss of Treg suppressor function seems to play
a critical role in MS disease pathogenesis [23,26,27,33].
Contemporary immunomodulatory drugs such as interferons
and glatiramer acetate have been suggested to mediate their
beneficial effects – at least partially - via modulation of Treg
frequency and/or suppressive function, thereby augmenting the
corollary of reconstituting Treg function as a therapeutic aim in
MS [34–37]. Integrins including alpha-4 integrin (VLA-4) are so
called bi-directional signalling molecules that connect to the
cytoskeleton and activate intracellular signalling pathways [10].
Ligation of VLA-4, which forms an essential part of the
immunological synapse, was demonstrated to provide costimula-
tory signals to T cells [11–13] and anti-VLA-4 therapy was
suggested to modulate the activation of lymphocytes in exper-
imental animal models of MS [25]. Accordingly, direct effects of
Natalizumab on the homeostasis of Tregs and their immunobi-
ological functions appear feasible. Our data clearly show, that the
frequency of Foxp3+ T cells as well as mRNA for FOXP3 within
the peripheral blood of patients was unaffected by therapy,
excluding that the beneficial effects of Natalizumab are largely due
to quantitative changes in the regulatory T cell population. Tregs
derived from MS patients were found to be poor suppressors
corroborating previously published data on a dysfunction of Tregs
in RRMS by several groups including ours [23,26,27]. Neither in
vitro VLA-4 blockade nor in vivo Natalizumab treatment restored
the impaired function of Tregs in suppression assays using anti-
CD3/CD28 coated bead as a stimulus. Previously Natalizumab
was reported to elicit costimulatory effects [13]. Therefore, before
analyzing its effects on Treg mediated suppression, we had to
exclude that VLA-4 blockade interferes with T effector cell
proliferation which would have biased the outcome of suppression
assays. In our hands a saturating dose of Natalizumab neither
enhanced nor diminished the proliferation of DC stimulated T
cells. According to the literature costimulatory effects of anti-VLA-
4 are subject to an inverse dose-dependency: very low doses of
anti-VLA-4 (0,1 mg/ml) strongly enhance PBMC proliferation,
while this effect seems to be diminished when higher doses of the
mAb are employed. In our study we used 20 mg/ml which is
within the range of serum trough levels of Natalizumab treated
patients and saturated Natalizumab binding sites on T cells
according to our own observations. To ensure the in vivo relevance
of our findings we did not employ lower doses which may explain
the lack of effects of Natalizumab on T effector cell proliferation in
our experiments. Accordingly, we challenged whether Natalizu-
mab may influence the outcome of immune responses by
modulating DC Treg interactions. Although we observed a weak
tendency towards an improvement of Treg function under
therapy, a level of significance was not reached.
One has to mention that it may not be the entire Foxp3+
population of T regulatory that is dysfunctional in MS. A lot of
research effort is currently put into identifying markers that may
characterize a specific subset among Foxp3+ Tregs that is
impaired in MS. Borsellino and colleagues recently reported a
subpopulation of Foxp3+ Tregs with potent suppressive function
identified by expression of the ectonucleotidase CD39. Although
the overall frequency of Foxp3+ Tregs did not differ between
healthy donors and MS patients, numbers of this specific subset
were greatly reduced [38]. Similarily, Haas et al. have reported
reduced numbers of a subset of naive Tregs that they defined as
recent thymic emigrants by the expression of CD31. Lack of this
subset was compensated for by increased numbers of memory
Tregs in MS patients, suggesting that this dysequilibrium in the
homeostatic composition may account for the impaired suppres-
sive function of Foxp3+ Tregs in MS [39]. Albeit merely
speculative, Natalizumab effects on a subset of Foxp3+ Tregs
may have accounted for the positive trend observed in our DC-
based suppression assays. Further studies unravelling Treg
dysfunction by characterization of impaired subsets are eagerly
awaited.
Summarizing, this is the first study prospectively analyzing the
effects of Natalizumab therapy on frequency and function of
regulatory T cells. Analysis of the impact of Natalizumab on
immune cell function is essential not only for understanding its
mechanisms of actions but also to clarify its role in the
pathogenesis of progressive multifocal leukencephalopathy. We
further add to the understanding of the mechanisms of action of
Natalizumab by demonstrating that unlike other immunomodu-
latory drugs the beneficial therapeutic effects of the monoclonal
antibody are largely independent of alterations in Treg frequency
or function.
cells derived from healthy donors (n=5) and Natalizumab treated patients (n=5 for each time point except month 6: n=3) before (M0), 1 month
(M1), 3 months (M3) and 6 months after initiation of therapy. Bars show the proliferation of responder cells (CD4+CD252) in the presence of Tregs
(1:10 Treg to T effector ratio) after normalization to the proliferation of responder cells in the presence of an equal number of non-regulatory T cells. *
p,0,05; Significant differences in suppression are observed comparing HD and RRMS Tregs at any time point during the treatment period, as
exemplarily depicted for M0. (C) Percentage of proliferating T effector cells derived from healthy donors (n=5) that were challenged by immature or
mature dendritic cells (DC : T cell ratio 1:5) in the presence or absence of Natalizumab (20 mg/ml). (D) In vitro addition of Natalizumab (20 mg/ml) does
not affect Treg mediated suppression of T cell proliferation in response to immature allogeneic DC as analyzed in CFSE suppression assays. Data were
normalized to the proliferation of T cells in response to DC in the presence of an equal number of non-regulatory T cells. (E) Proliferation of responder
cells from healthy controls (HD, n=4), and RRMS patients before (M0, n=4), 1 month (M1, n=4) and six months (M6, n=4) after initiation of
Natalizumab treatment. Normalization as in (D).
doi:10.1371/journal.pone.0003319.g004
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Clinical Samples
The study was approved by the local ethics committee (Ethics
committee Wuerzburg) and written consent was obtained from all
participants (Nr. 155/06). Natalizumab treatment was initiated in
relapsing-remitting (RR)MS patients because of highly active
disease that was refractory to treatment with approved disease
modifying agents. Peripheral blood was obtained by vein puncture
at specific time points before and after initiation of Natalizumab
therapy as indicated below. All patients had been on immunmo-
dulatory or immunosuppressive therapy prior to initiation of
Natalizumab therapy. Interferon beta and glatiramer acetate were
stopped at least 15 days before starting the patients on
Natalizumab. Immunosuppressive therapy had to be terminated
at least 6 months prior and normalization of blood counts was
required before initiation of Natalizumab therapy. Patients with
clinically definite RRMS either with a documented stable disease
course (.6 months) or acute relapse and healthy volunteers served
as a control group.
Isolation of peripheral blood mononuclear cells,
purification of T cell subsets and generation of dendritic
cells
PBMC were isolated by centrifugation on a Lymphoprep
TM
(Fresenius Kabi Norge AS, Oslo, Norway) density gradient. To
allow comparative analysis in a prospective, longitudinal study
design, PBMC were immediately cryopreserved and stored in
liquid nitrogen. CD4+ T cells were isolated using MACSH
technology (CD4+ T cell isolation kit II, Miltenyi, Bergisch-
Gladbach, Germany) according to the manufacturer’s protocol.
For purification of Tregs different methods had to be evaluated.
Cryopreservation has been shown to reduce CD25 immunoreac-
tivity on Tregs [18]. Since CD25 surface expression is mandatory
for purification of Tregs, PBMC were allowed to recover over a 3
day culture period, until CD25 surface levels were fully restored.
PBMC were subjected to magnetic cell separation using the CD4+
CD25+ regulatory T cell isolation kit (Miltenyi) or to fluorescence
activated cells sorting gating on CD4+CD25
high or
CD4+CD25
highCD127
low respectively (MoFlo Sampler, Dako,
Glostrup, Denmark; FACSDiva, BD Bioscience, Heidelberg,
Germany). The following antibodies were used: anti-CD4 (SK3),
anti-CD127 (hIL-7R-M21), anti-CD25 (M-A251) (all from BD
Biosciences, Heidelberg, Germany). Monocytes were selected by
adhesion to plastic flasks for 1 h. Dendritic cells were generated as
previously described .[19]. In brief, monocytes were cultured in
RPMI 10% FCS supplemented with GM-CSF (100 ng/ml) and
IL-4 (40 ng/ml) (both from R&D Systems, Minneapolis, MN,
USA). After 5 days, the cells exhibited an immature DC
phenotype as assessed by flow cytometry for CD80, CD86,
MHC II and DC-SIGN. Maturation was induced by 48h-
incubation of the immature DCs with LPS (5 mg/ml). High levels
of surface MHC class II and costimulatory molecules (CD86,
CD80), as well as low levels of DC-SIGN identified mature DCs.
Flow cytometry
Cells were washed twice in phosphate buffered saline (PBS)
containing 0.1% sodium azide and 1% bovine serum albumine,
followed by Fc receptor blocking with human IgG (Sigma-Aldrich,
Munich, Germany). Afterwards cells were incubated for 30 min-
utes with specific monoclonal antibodies. The following anti-
human monoclonal antibodies were used (all fluorochrome-
conjugated): anti-CD4 (SK3), anti-CD8 (SK1), anti-CD49d
(9F10), anti-CD127 (hIL-7R-M21), anti-CD25 (M-A251) (all from
BD Biosciences, Heidelberg, Germany) and anti-CD4 (M-T466)
(from Ebioscience, San Diego, USA). The respective isotype
controls (IgG1, rat IgG2a) were purchased from BD Biosciences.
Intracellular stainings using anti-Foxp3 (PCH101) antibody were
performed using a Foxp3 staining kit (Ebiosciences, San Diego,
CA, USA) according to the manufacturer’s protocol. All antibodies
were titrated for optimal concentrations. A FACSCalibur flow
cytometer (BD, Heidelberg, Germany) was used. Data was
analyzed using FlowJo software (Tree Star Inc. Ashland, OR,
USA). Histograms were analyzed by calculating the specific
fluorescence index (SFI) [geometric mean of the specific antibody
fluorescence divided by the geometric mean of the isotype control
antibody fluorescence].
Natalizumab binding assay
Natalizumab was labelled with fluorescein isothiocyanate
(FITC) using the EZ-Label
TM FITC Protein Labelling Kit (Pierce,
Rockford, USA) according to the manufacturer’s instructions.
Cells were incubated with 20 mg/ml of Natalizumab for 30 min,
followed by staining for additional surface makers and analyzed by
multicolour flow cytometry. Binding of Natalizumab-FITC was
completely abrogated in the presence of a 10 fold excess of
unlabeled Natalizumab, which was used as a negative control in
each donor to calculate the specific fluorescence index (SFI).
Analysis of FOXP3 mRNA levels by quantitative real-time
PCR
RNA was isolated using the RneasyH Mini Kit (Qiagen, Hilden,
Germany). 500 ng of mRNA were transcribed using random
hexamers and MuLV reverse transcriptase (all reagents supplied
by Applied Biosystems, Foster City, USA). Gene expression assays
for the detection and quantification of FOXP3 (Hs00174114_m1)
and the housekeeping gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) were purchased from Applied Biosystems and
used according to the manufacturer’s protocol. The Applied
Biosystems 7500 fast real-time PCR system was used, all samples
were run in duplicates and each run contained several negative
controls (no template) and a reference sample. There were no
significant differences in cycle threshold neither within nor
between the experiments. Quantification of gene expression was
performed according to the comparative cycle threshold method
(2
2DDCT) after validating the experiments by comparing the
amplification efficiencies of targets and housekeeping gene. All
samples were normalized to GAPDH and compared to a reference
sample used in all the experiments
Transmigration Assay
Transmigration was assessed in a well established assay [20–22].
Using 3-mm pore-size membranes (BioCoat
TM fibronectin coated
cell culture inserts (BD Biosciences)). Membranes were rehydrated
with RPMI 1640 for one hour at 37uC. 10
6 PBMCs or CD4+ T
cells suspended in 1 ml of RPMI 1640 plus 2.5% fetal calf serum
(FCS, PAA, Pasching, Austria), were added to the upper chamber.
The lower compartment was filled with 1,5 ml of RPMI 1640
supplemented with 10% FCS. After 12 hours at 37uC, contents of
the lower chamber were collected and processed for flow
cytometry. The frequency of CD4+ and CD4+Foxp3+ T cells
was determined before migration (baseline) and within the
migrated fraction.
Treg suppression assay
Suppressive function of Tregs was assessed by using an
optimized autologous suppression assay [23,24]. CD4+CD25
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succinimidylester (CFSE) using the VybrantHCFDA-SE Cell
Tracer Kit (Invitrogen, Karlsruhe, Germany). Anti-CD3/anti-
CD28 coated beads (Dynabeads, Invitrogen, Karlsruhe, Germany
were used as a stimulus. Stimulus-responder and responder-Treg
ratios were carefully titrated to achieve suboptimal suppression.
5610
4 CFSE labelled CD4+CD252 were cocultured with 5610
3
CD4+CD25
highCD127
low or the same number of irradiated
CD4+CD252 as a control for unspecific suppression and
Dynabeads (Invitrogen, Oslo, Norway) at a ratio of 1 bead per
50 cells in the absence or presence of Natalizumab.
To investigate suppression in the presence of antigen-presenting
cells, autologous CD4+CD252 and CD4+CD25
highCD127
low T
cells were cocoultured with allogeneic immature and mature
dendritic cells at a T cell to DC ratio of 5 to 1 in the presence of
2,5 mg/ml anti-CD3 (clone: UCHT1, Ebioscience, San Diego,
USA) and 2,5 mg/ml anti-CD28 (clone: CD28.2, Ebioscience, San
Diego, USA) in 96 well plates precoated with 5 mg/ml aCD3 for at
least 2 hours at 37uC. After 96 hours the percentage of
proliferating responder cells as reflected by CFSE dilution was
assessed by flow cytometry. The percentage of proliferating cells in
the presence of Tregs was normalized to proliferation of responder
cells in the presence of an equal number of irradiated non-
regulatory T cells.
Statistics
All data sets were analyzed using student’s t-test. *, p,0.05; **,
p,0.005
Supporting Information
Figure S1 The relative decrease in CD49d immunoreactivity on
CD4+ T cells under Natalizumab therapy is remarkably
diminished after development of persistent neutralizing antibodies
in 1 patient with RRMS. CD49d surface expression was analyzed
by flow cytometry before (M0), one month after the first infusion
(M1) and 6 months after initiation of therapy (M6). Neutralizing
antibodies were first detected 16 weeks after the first infusion and
confirmed in the re-test 6 weeks later.
Found at: doi:10.1371/journal.pone.0003319.s001 (0.43 MB TIF)
Figure S2 (A) Intracellular Foxp3 levels after human T
regulatory cell purification using MACS technology (left panel)
or fluorescence activated cell sorting using CD4 and CD25 as
markers (right panel). Histograms show the purity of the
populations yielded by this isolation procedures (light grey:
CD4+CD252 effector cells, dark grey: CD4+CD25high, one
representative example is shown). (B) Example of fluorescence
activated flow cytometric cell sorting of Tregs using CD4, CD127
and CD25 as markers (left). This strategy yields a highly pure
population of Foxp3 expressing T regulatory cells as evidenced by
intracellular staining for the transcription factor Foxp3 (histogram,
light grey CD4+CD252 effector cells, dark grey:
CD4+CD127lowCD25high).
Found at: doi:10.1371/journal.pone.0003319.s002 (1.42 MB TIF)
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